Stock Ratings / Health Care / EPRX / forecast

SSII (39) BWAY (61) MNPR (31) BLSM (46) ⌘ Pro Terminal →

Eupraxia Pharmaceuticals Inc. (EPRX) 12-Month Stock Forecast & Price Target Cone

$7.25 -1.76% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.21

Eupraxia Pharmaceuticals Inc. (EPRX) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $477.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $7.21 (-0.51%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EPRX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY EPRX SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$7.46-11.3% Next Q

Q2 (-2Q)

Grade D$6.62+3.8% Next Q

Q3 (-1Q)

Grade E$6.87+5.5% Next Q

Current

Grade D-$7.25-8.3% Hist 90D α

Trajectory: D (44) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EPRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EPRX currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.59) and Max Pain ($7.61) forces dealer call-delta covering toward $9.79.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EPRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EPRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your EPRX Position Size: $10,000

Shares at $7.25: 1379.3 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $5.09

$7,021

$-2,979 (-29.8%)

12M Consensus BaseTarget $6.53

$9,007

$-993 (-9.9%)

12M Bull Case BreakoutTarget $9.79

$13,503

+$3,503 (+35.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$7	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$9	69%	B
JP MorganUS Large-Cap Research	SELL	$6	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EPRX)

✓Walkthrough of EPRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EPRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.05%▲ ASCENDING CHANNEL

2026-10-30O $7.10H $7.25L $6.41C $7.25VOL 1.22M

RES: $10.01SUP: $6.45SMA50: $7.59SMA200: $7.31

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EPRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EPRX Butterfly Map → + Track EPRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EPRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EPRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EPRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EPRX)

Health Care Rank #781 of 1016 ⚔️ SSII vs EPRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EPRX vs. SSII, BWAY, MNPR, BLSM)

Industry: Pharmaceuticals and Biotechnology (1 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Eupraxia Pharmaceuticals Inc. (EPRX) ranks #781 by composite RQD confidence (36/100, grade D-) and #462 by equity capitalization ($477.8M). Within this direct 5-issuer industry benchmark cohort, EPRX leads on earnings valuation at N/A trailing P/E, while MNPR leads on capital efficiency and profitability with -17.4% ROIC and — gross margin. BWAY currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with EPRX at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EPRX ACTIVE Eupraxia Pharmaceuticals Inc.	D-	36/100	—	—	-35.0%	-1.76%	$477.8M	Benchmark Subject
SSII SS Innovations International Inc.	D-	39/100	—	46.0%	-18.5%	-2.46%	$477.2M	/ssii-vs-eprx →
BWAY BrainsWay Ltd.	C-	61/100	—	—	—	+4.93%	$478.7M	/bway-vs-eprx →
MNPR Monopar Therapeutics Inc.	E	31/100	—	—	-17.4%	-2.02%	$482.7M	/mnpr-vs-eprx →
BLSM BlossomHill Therapeutics Inc.	D	46/100	—	—	—	-7.59%	$483.4M	/blsm-vs-eprx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001581178

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eupraxia Pharmaceuticals Inc. (EPRX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$38.6M, operating cash flow of -$28.6M, and free cash flow of -$28.6M (+4.8% YoY). On the balance sheet, EPRX closed FY2025 with $86.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$38.6M	-$28.6M	-$28.6M	$86.2M	—
FY2024 (FY)	2024-12-31	$0	-$25.5M	-$30.0M	-$30.0M	$34.9M	—
FY2023 (FY)	2023-12-31	$0	-$28.2M	-$20.7M	-$20.7M	—	—

3. EPRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EPRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $7.25 (-1.76% 1D, market cap $477.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EPRX ranks #781 in composite RQD confidence.

How does EPRX compare to SSII and BWAY in the Health Care sector?

Within the Health Care sector (Pharmaceuticals and Biotechnology), EPRX carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SSII (SS Innovations International Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -18.5%, cap $477.2M) and BWAY (BrainsWay Ltd.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $478.7M). Among the 5-stock peer group, EPRX leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EPRX?

Per EPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001581178), Eupraxia Pharmaceuticals Inc. generated $0 in revenue, -$38.6M in net income, and -$28.6M in free cash flow against $86.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EPRX trading relative to its 50-day, 200-day, and 52-week technical levels?

EPRX last traded at $7.25 (-1.76% on volume of 1,015,484 shares), positioning the stock -4.48% below its 50-day simple moving average ($7.59) and -0.82% below its 200-day simple moving average ($7.31). Across its 52-week range of $5.25 to $9.32, EPRX sits at the 49.1% percentile with a 14-day RSI of 43.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.34 to $8.16).

EPRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is EPRX's 12-month stock price target?

Eupraxia Pharmaceuticals Inc. (EPRX) carries a 12-month consensus base price target of $6.53 (-9.9% from $7.25), with a bull-case target of $9.79 and a bear-case floor of $5.09.

Is EPRX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates EPRX D- (Sell — SELL) with an RQD Confidence score of 36/100.

Direct Sub-Reports: EPRX RQD Cockpit EPRX 12M Forecast EPRX Earnings & Move EPRX Dividends & DRIP EPRX Insiders & 13F EPRX Whale Options EPRX Profit Sankey EPRX News & Why